**Listing of Claims:**

1-31. (cancelled)

32. (new) A compound of formula



(I)

a *N*-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein :

p represents an integer being 0, 1, or 2;

q represents an integer being 0, 1, or 2;

X represents O, S, $NR^3$ or a direct bond;

$R^1$ represents hydrogen, hydroxy, halo, amino, $C_{1-6}$alkyl, $C_{1-6}$alkyloxy or mono- or di($C_{1-4}$alkyl)amino$C_{1-4}$alkylamino; in particular, hydrogen, methyl and hydroxy;

$R^2$ represents oxadiazolyl, thiazolyl, pyrimidinyl or pyridinyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from $Het^2$, $R^{11}$ and $C_{1-4}$alkyl optionally substituted with $Het^2$ or $R^{11}$;

each $R^4$ independently represents $C_{1-6}$alkyl, halo, polyhalo$C_{1-6}$alkyl or $C_{1-6}$alkyloxy;

each $R^5$ independently represents $C_{1-6}$alkyl, halo or $C_{1-6}$alkyloxy;

each $R^6$ independently represents $C_{1-6}$alkylsulfonyl, aminosulfonyl or phenyl$C_{1-4}$alkylsulfonyl;

each $R^7$ and each $R^8$ are independently selected from hydrogen, $C_{1-4}$alkyl, hydroxy$C_{1-4}$alkyl, dihydroxy$C_{1-4}$alkyl, aryl, aryl$C_{1-4}$alkyl, $C_{1-4}$alkyloxy$C_{1-4}$alkyl, mono- or di($C_{1-4}$alkyl)amino$C_{1-4}$alkyl, arylaminocarbonyl, arylaminothiocarbonyl, $C_{3-7}$cycloalkyl, pyridinyl$C_{1-4}$alkyl, $Het^3$ and $R^6$;

$R^9$ and $R^{10}$ are each independently selected from hydrogen, $C_{1-4}$alkyl, $C_{1-4}$alkylcarbonyloxy$C_{1-4}$alkylcarbonyl, hydroxy$C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonylcarbonyl, $Het^3$aminothiocarbonyl and $R^6$;

each $R^{11}$ independently being selected from hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, $C_{1-4}$alkyloxy, carboxyl, $C_{1-4}$alkyloxycarbonyl, trihalo$C_{1-4}$alkylsulfonyloxy, $R^6$, $NR^7R^8$, $C(=O)NR^7R^8$, aryl, aryloxy, arylcarbonyl, $C_{3-7}$cycloalkyl, $C_{3-7}$cycloalkyloxy, phthalimide-2-yl, $Het^3$ and $C(=O)Het^3$;

$R^{12}$ and $R^{13}$ are each independently selected from hydrogen and $C_{1-4}$alkyl;

aryl represents phenyl optionally substituted with one, two or three substituents each independently selected from nitro, azido, halo, hydroxy, $C_{1-4}$alkyl, $C_{1-4}$alkyloxy, polyhalo$C_{1-4}$alkyl, $NR^9R^{10}$, $R^6$, phenyl, $Het^3$ and $C_{1-4}$alkyl substituted with $NR^9R^{10}$;

$Het^1$ represents a heterocycle selected from a heterocycle selected from imidazolyl, triazolyl, furanyl, oxazolyl, thiazolyl, thiazolinyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, piperidinyl, piperazinyl, triazinyl, benzothiazolyl, benzoxazolyl, purinyl, 1*H*-pyrazolo-[3,4-d]pyrimidinyl, benzimidazolyl, thiazolopyridinyl, oxazolopyridinyl, imidazo-[2,1-b]thiazolyl; wherein said heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from $Het^2$, $R^{11}$ and $C_{1-4}$alkyl optionally substituted with $Het^2$ or $R^{11}$;

$Het^2$ represents furanyl, thienyl or pyridinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with $C_{1-4}$alkyl;

$Het^3$ represents pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl; wherein said monocyclic heterocycles each independently may optionally be substituted with, where possible, one, two or three substituents each independently selected from $C_{1-4}$alkyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyl, phenyl$C_{1-4}$alkyl, piperidinyl, $NR^{12}R^{13}$ and $C_{1-4}$alkyl substituted with $NR^{12}R^{13}$.

33. (new) A compound according to claim 32 wherein the 6-azauracil moiety is in the para position relative to the central carbon atom.

34. (new) A compound according to claim 33 wherein q is 1 or 2 and one $R^4$ substituent is in the 4 position; and p is 1 or 2 and the one or two $R^5$ substituents are in the ortho position relative to the central carbon atom.

35. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 32.

36. (new) A process for preparing a composition as claimed in claim 35, wherein a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in claim 32.

37. (new) A method for treating one or more of bronchial asthma, atopic dermatitis, allergic-rhinitis or allergic conjunctivitis in a warm-blooded animal in need thereof comprising administering to the warm-blooded animal an effective amount of a compound of claim 32.

38. (new) A method for inhibiting IL-5 production in a warm-blooded animal, comprising administering to the warm-blooded animal an effective amount of a compound of claim 32.